(Q43873385)

English

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

scientific article published on 23 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

2

object named as

Marc Decramer

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

Jadwiga A Wedzicha

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Joachim H Ficker

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Dennis E Niewoehner

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Thomas Sandström

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Angel Fowler Taylor

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Peter D'Andrea

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Christie Arrasate

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Hungta Chen

9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Donald Banerji

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

199-209

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Physical activity and hospitalization for exacerbation of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Exacerbations and time spent outdoors in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardisation of spirometry

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Longitudinal changes in the nature, severity and frequency of COPD exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of bronchodilator treatment in the prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of preventing exacerbations on deterioration of health status in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970052-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(13)70052-3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43873385&oldid=2105504657"